Bradycardia Clinical Trial
— MHYHOfficial title:
Project My Heart Your Heart: Prospective Evaluation of the Safety and Efficacy of Cardiac Pacemaker Reuse in Low to Middle Income Countries
Verified date | September 2023 |
Source | University of Michigan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Lack of access to pacemakers is a major challenge to the provision of cardiovascular health care in Low and Middle Income Countries (LMIC). Post-mortem pacemaker utilization could be safe, efficacious, and ethically responsible means of delivering the needed care. Reconditioned pacemakers can provide therapy for patients with symptomatic bradycardia and no means of receiving a new device. The objective of the clinical trial is to determine if pacemaker reutilization can be shown to be a safe means of delivering pacemakers to patients in LMIC without resources. Consented patients in this multi-center trial will be randomized to undergo implantation of either a reconditioned device or a new device.
Status | Enrolling by invitation |
Enrollment | 260 |
Est. completion date | October 2024 |
Est. primary completion date | October 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Life expectancy = 2 years. - Indications for device implantation must be fulfilled per standard of care. Consistent with 2008 American College of Cardiology / American Heart Association guidelines for device therapy, one of the following class I indications must be met. - Sinus Node Dysfunction - Acquired Atrioventricular (AV) Block - Chronic Bifascicular Block - Hypersensitive Carotid Syndrome - Lack of financial ability to pay for a new device must be assessed and documented. - All other methods of new device acquisition must be exhausted. - Patient must be agreeable and able to follow-up with the implanting center within 2 weeks for wound check, at 2 months, 6 months, and every 6 months thereafter for routine pacemaker checks. Exclusion Criteria: - Severe valvular disease - Severe pulmonary disease - End-stage renal disease (creatinine clearance < 30 mL/min) whether or not on dialysis - Evidence of ongoing systemic infection - Prior pacemaker or implantable cardioverter-defibrillator implantation - Significant contraindication to pacemaker implantation per evaluation of the implanting physician (very high risk of complications). - Presence of any other condition that the local investigator feels would be problematic or would restrict or limit the participation of the patient for the entire study period - Pregnant women |
Country | Name | City | State |
---|---|---|---|
Kenya | The Moi Teaching and Referral Hospital | Eldoret | |
Nigeria | LASUTH | Ikeja | Lagos |
Nigeria | Port Harcourt Teaching Hospital | Port Harcourt | Rivers |
Paraguay | FUNDACOR | Asunción | |
Sierra Leone | Choithram Memorial Hospital | Freetown | |
Venezuela | ASCARDIO | Barquisimeto | Lara |
Lead Sponsor | Collaborator |
---|---|
University of Michigan |
Kenya, Nigeria, Paraguay, Sierra Leone, Venezuela,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Freedom from Procedure-Related Infection at 12 months | Clinical evidence of pacemaker infection includes local signs of inflammation at the generator site such as erythema, warmth, fluctuance, tenderness, purulent drainage, wound dehiscence, or erosion. Device related endocarditis will be reported if the Duke criteria for infective endocarditis are met. Procedure-related infections will be classified as follows: pocket infection, endocarditis, recurrent bacteremia, extrusion of wires or generator | 12 months post device implantation | |
Secondary | Freedom from Pacemaker Software or Hardware Malfunction at 12 months | Pacemaker software or hardware malfunction include unexpected premature battery depletion, device or electrode malfunction, or unexplained patient death. | 12 months post device implantation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03922386 -
Safety and Electrical Performances of XFINE Leads
|
N/A | |
Completed |
NCT03294018 -
Heart Rate Changes Following the Administration of Sugammadex
|
||
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Not yet recruiting |
NCT05440071 -
PoSt-market Assessment on Safety and Performance of J-sHAPed xFINE Lead
|
||
Completed |
NCT02153242 -
The Effects of Selective Site Right Ventricular Pacing
|
||
Recruiting |
NCT01825473 -
Study of Erythromycin in GER-Associated Apnea of the Newborn
|
N/A | |
Completed |
NCT00950287 -
Detection of Neonatal Bradycardia
|
N/A | |
Completed |
NCT00721136 -
Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation
|
N/A | |
Completed |
NCT00286858 -
Beluga - Clinical Observations of Automatic Algorithms for Cardiac Pacing
|
||
Completed |
NCT00158925 -
The EASYTRAK EPI Clinical Investigation
|
Phase 3 | |
Completed |
NCT00180557 -
Austria Study - Analysis of Difference Between Active and Passive Fixation Leads
|
Phase 4 | |
Completed |
NCT01076348 -
Model 4965 Post-Approval Study
|
||
Completed |
NCT04198220 -
BIO|STREAM.ICM Obesity
|
||
Recruiting |
NCT05298748 -
The Effect of Womb Recordings on Maturation of Respiratory Control in Preterm Infants
|
N/A | |
Recruiting |
NCT04353960 -
The Alaska Oculocardiac Reflex Study
|
||
Terminated |
NCT04093414 -
Left Bundle Area Versus Selective His Bundle Pacing
|
N/A | |
Completed |
NCT03786640 -
Abbott Brady 3T MRI PMCF
|
||
Recruiting |
NCT05932602 -
AVEIR DR Coverage With Evidence Development (CED) Study
|
||
Recruiting |
NCT05935007 -
Aveir DR Real-World Evidence Post-Approval Study
|
||
Recruiting |
NCT04075084 -
Observation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs)
|